Budipine

Budipine

Systematic (IUPAC) name
1-tert-butyl-4,4-diphenylpiperidine[1]
Clinical data
AHFS/Drugs.com	International Drug Names
Identifiers
CAS Number	57982-78-2
ATC code	N04BX03 (WHO)
PubChem	CID 68778
ChemSpider	62021
UNII	L9026OPI2Z
KEGG	D07306
ChEMBL	CHEMBL334491
Chemical data
Formula	C21H27N
Molar mass	293.446 g/mol
SMILES c1(ccccc1)C3(c2ccccc2)CCN(C(C)(C)C)CC3
InChI InChI=1S/C21H27N/c1-20(2,3)22-16-14-21(15-17-22,18-10-6-4-7-11-18)19-12-8-5-9-13-19/h4-13H,14-17H2,1-3H3 Key:QIHLUZAFSSMXHQ-UHFFFAOYSA-N
(verify)

Budipine (brand name Parkinsan) is an antiparkinson agent marketed for the treatment of Parkinson's disease.^[2][3]

While its exact mechanism of action is not well characterized,^[2] it is believed to be an NMDA receptor antagonist,^[4][5] but also promoting the synthesis of dopamine.^[6]

Because it provides additional benefits relative to existing treatments, it probably does not precisely mimic the mechanism of an existing known treatment.^[6][7]

See also

• AD-1211
• Delucemine
• Diphenidine
• Ephenidine
• Fluorolintane
• Lanicemine
• Methoxphenidine (MXP)
• MT-45
• Remacemide

References

1. Martndale: The Complete Drug Reference, 35th Ed.
2. Heinz Reichmann (October 2006). "Budipine in Parkinson's tremor.". Journal of the Neurological Sciences 248 (1-2): 53–55. doi:10.1016/j.jns.2006.05.039. PMID 16784759.
3. H. Przuntek, T. Müller (1999). "Clinical efficacy of budipine in Parkinson's disease.". Journal of Neural Transmission. Supplementa 56: 75–82. doi:10.1007/978-3-7091-6360-3_3. PMID 10370903.
4. J. Kornhuber, B. Herr, J. Thome, P. Riederer. "The antiparkinsonian drug budipine binds to NMDA and sigma receptors in postmortem human brain tissue". J.Neural Transm.Suppl. 46:127-133, 1995. PMID 8821048
5. Gene C. Palmer (September 2001). "Neuroprotection by NMDA receptor antagonists in a variety of neuropathologies.". Current Drug Targets 2 (3): 241–271. doi:10.2174/1389450013348335. PMID 11554551.
6. Przuntek H, Bittkau S, Bliesath H; et al. (May 2002). "Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen". Arch. Neurol. 59 (5): 803–6. doi:10.1001/archneur.59.5.803. PMID 12020263.
7. Jenny C.E. Owen, Peter S. Whitton (October 2006). "Effects of amantadine and budipine on antidepressant drug-evoked changes in extracellular dopamine in the frontal cortex of freely moving rats.". Brain Research 1117 (1): 206–212. doi:10.1016/j.brainres.2006.07.039. PMID 16996043.